Christine I Chen
Overview
Explore the profile of Christine I Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
308
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bell J, Jeffries G, Chen C
Blood
. 2023 Aug;
142(15):1263-1270.
PMID: 37540818
Manufacturing capacity and institutional infrastructure to deliver chimeric antigen receptor T-cell therapies (CAR-T) are pressured to keep pace with the growing number of approved products and expanding eligible patient population...
2.
Schiller G, Lipe B, Bahlis N, Tuchman S, Bensinger W, Sutherland H, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Jul;
23(9):e286-e296.e4.
PMID: 37393120
Background: The increasing use of anti-CD38 monoclonal antibodies (αCD38 mAbs) for newly diagnosed or early relapsed multiple myeloma (MM), especially in non-transplant eligible patients, may lead to more patients developing...
3.
Baljevic M, Gasparetto C, Schiller G, Tuchman S, Callander N, Lentzsch S, et al.
EJHaem
. 2022 Dec;
3(4):1270-1276.
PMID: 36467792
There is a lack of consensus on therapy sequencing in previously treated multiple myeloma, particularly after anti-B-cell maturation antigen (BCMA) therapy. Earlier reports on selinexor (X) regimens demonstrated considerable efficacy...
4.
Kaedbey R, Forward N, Sehn L, Shafey M, Doucette S, Chen C
Curr Oncol
. 2022 Oct;
29(10):7122-7139.
PMID: 36290837
Waldenström macroglobulinemia (WM) is a slowly progressing B-cell non-Hodgkin lymphoma characterized by monoclonal IgM gammopathy in the blood and infiltration of the bone marrow by clonal lymphoplasmacytic cells. As an...
5.
Gasparetto C, Schiller G, Tuchman S, Callander N, Baljevic M, Lentzsch S, et al.
Br J Cancer
. 2021 Nov;
126(5):718-725.
PMID: 34802051
Background: Proteasome inhibitors (PIs), including carfilzomib, potentiate the activity of selinexor, a novel, first-in-class, oral selective inhibitor of nuclear export (SINE) compound, in preclinical models of multiple myeloma (MM). Methods:...
6.
Chen C, Cao Y, Trudel S, Reece D, Kukreti V, Tiedemann R, et al.
Leuk Lymphoma
. 2020 Jun;
61(8):1860-1868.
PMID: 32476520
Lenalidomide is a backbone agent in the treatment of multiple myeloma, but dose adjustment is required for those with renal impairment (RI). We evaluated the pharmacokinetics (PK) and safety of...
7.
Li A, Atenafu E, St Bernard R, Masih-Khan E, Reece D, Franke N, et al.
Bone Marrow Transplant
. 2019 Sep;
55(3):578-585.
PMID: 31558786
Autologous stem cell transplant (ASCT) is a feasible treatment option for multiple myeloma (MM) patients with renal insufficiency; however, these patients tend to experience higher rates of drug toxicity and...
8.
Chen C, Paul H, Snitzler S, Kakar S, Le L, Wei E, et al.
Leuk Lymphoma
. 2018 Oct;
60(4):980-989.
PMID: 30277089
Lenalidomide has anti-tumor activity in CLL but can be complicated by tumor lysis syndrome (TLS) and tumor flare (TF). In our previous study using low-dose lenalidomide in treatment-naive CLL, TLS...
9.
Chen C, Paul H, Le L, Wei E, Snitzler S, Wang T, et al.
Leuk Lymphoma
. 2018 Jun;
60(1):92-100.
PMID: 29916761
AKT plays a centralized role in tumor proliferation and survival and is aberrantly activated in chronic lymphocytic leukemia (CLL). In this phase 2 trial, 30 relapsed/refractory CLL patients were treated...
10.
Malavade T, Cassol C, John R, Husain S, Chen C, Chan C
Kidney Int Rep
. 2018 Jun;
3(3):748-751.
PMID: 29854985
No abstract available.